SGLT2 inhibitors may reduce risk of lupus complications

Sodium-glucose cotransporter-2, or SGLT2, inhibitors may be effective at reducing the risk of lupus nephritis and other complications in patients with systemic lupus erythematosus, according to a study published in JAMA Network Open.

Investigators used the U.S. Collaborative Network of the TriNetX clinical data platform to analyze the outcomes of 1,775 matched pairs of patients with lupus and Type 2 diabetes who received or didn’t receive treatment with SGLT2 inhibitors.

Compared with the patients who didn’t receive the treatment, the investigators found that the patients who received SGLT2 inhibitors were less likely to experience lupus nephritis, dialysis, kidney transplant, heart failure and all-cause mortality.

The investigators proposed that SGLT2 inhibitors should be considered in patients with lupus and Type 2 diabetes at risk of lupus nephritis or other adverse kidney or cardiac outcomes.

Read more: JAMA Network Open

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.